Pushing forward microbiome science in order to find ways to use our microbiota to prevent and treat human disease
Focused on Research in Microbiology, Immunology and Computational Biology - keys to understanding our microbiota and their interactions with us
Consortia Therapeutics develops microbial therapies to prevent and treat human disease and allergies.
Our work is based upon evidence-based studies from the Massachusetts Host Microbiome Center and the research of its scientific founders.
Consortia Therapeutics (CTX) focuses on the use of human colonizing microbes and microbial products to treat human diseases. The company’s first patented consortia are for the prevention and treatment of human food allergies. Food allergies are a major problem in the US and developing countries that affect 6% of kids and 3% of adults; major life threatening reactions can occur from exposure if the patients are allergic. The field as a whole lacks good therapies to prevent or cure pre-existing allergies - - rather patients are just supposed to avoid certain foods.